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The effect of topical application of FK506 on the 
normal hair cycle of C57BL!6] mice was investigated. 
When telogen mice (7 weeks of age) were treated 
topically with 1 /Lmol FK506 on days 0 and 3, 50% of 
the tested mice entered anagen by day 9 and 100% by 
day 16. With 0.1 /Lmol of FK506, 50% of the tested 
mice entered anagen by day 13 and 80% by day 19, 
indicating that the effect ofFK506 is dose dependent. 
In control mice, a spontaneous shift from telogen to 
anagen started on day 14, and 30% of the control 
animals were in anagen at day 19. Histologic stu dies 
revealed that FK506 markedly stimulated the skin 
and thickened it. The depth and size of hair follicles 
F K506, a macrolide antibiotic, is a T-cell-specific immu-nosuppressant [1,2]. Topical application ofFK506 stim-ulates hair growth in several species of animals, includ-ing mice [3] . In contrast, oral administration of FK506 at a dose that induces marked immunosuppression did 
not stimulate significant h air growth [3], consistent with the fact 
that FK506 does not induce hypertrichosis in clinical trials [4-7]. 
The hair-growth-stimulating effect of FK506 is due at least in part 
to its direct stimulation of hair follicles and may be essentially 
unre lated to its immunosuppressive e ffect [3] . Although at present 
the prec ise mec hanism of tlus hair-growth-stimulating e ffect is not 
clear, it seems important to examine the effect of FK506 on the 
normal hair cycle. Therefore, we investigated whether FK506 
induces anagen hair growth in telogen mouse skin. 
MATERJALS AND METHODS 
FK506 was supplied by Fujisawa Pharmaccutical Co. (Osaka. Japan) . 
Female C57BL/6j mice were purchased fi·ol11 japan C lea Co. (Tokyo, 
Japan). Mice were housed in an air-conditioned room (22-23 °C) with a 
light period from 6 AM to 6 I'M . Food and water were available ad liiJi/,III'. 
T he dorsal hair of each mouse was shaved with clippers at least 2 d before 
use. AU of the experiments wcre started at 7 weeks ofagc, when all the mice 
used were in tc logcn phase. FK506 (0.1 or 1 f-Lmol) was applied topica lly 
once cach on days 0 and 3. FK506 was dissolved in acetonc and applied to 
the shaved area in a volumc of 0.2 ml using a micropipet. The control 
animals were treated topica lly with 0.2 ml of acctone alonc. The area of 
dorsal skin treated with FK506 was approximately 3 cm 2 . 
The anagen induction assay was performed as descl;bcd by Paus el al (8). 
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were also markedly increased in FK506-treated skin 
compared to control skin. The data on hair growth 
also support the contention that FK506 induces early 
onset of anagen and stimulates hair growth. The hair 
growth stimulated by FK506 looked normal and the 
hairs were of normal length. The hair growth was 
restricted to the site of application. These results 
clearly demonstrate that topical application ofFK506 
induces anagen hair growth in telogen mouse skin 
and indicate that the hair-growth-stimulating effect 
ofFK506 is due at least in part to its promoting effect 
on the hair cycle. Key Ivords: hair growtlllhaiJ' follicle! 
C57BLl6] "lOlIse.] Invest Dermatol 104:523-525, 1995 
In brief, thc back skin of each mouse was observed once daily during the 
experiment. T he number of anima.is in telogcn or anagen. as judged by their 
skin color, i.e., bright pink in tclogen and gray to black in anagen. was 
counted and expressed as the percentage of animals in anagen . Each group 
consisted of '10 anima.is. Histologic examination also was conducted to 
confirm anagen induction. The skin was stretched and fixed in 10% 
formal.in, cmbeddcd in paraffin, and stained with hematoxylin and eosin. 
T hickness of the skin and depth of the hair fo llicles were measured 
m.icroscopically. T he length of dorsal hai rs also was measured. All of the 
experiments werc rcpcated twicc on different occasions using animals from 
different litters. The mice used were chosen randomly from 50-1 00 animals 
in each cxperiment. 
All cxperimcntal protocols werc approvcd by The Experimental An.imals 
Committee of Keio University School of Medicine. 
Statistical analysis was done by Student t tcst. 
RESULTS AND DISCUSSION 
At the age of 7 weeks, C57BL/6] mice h ad pink skin, indicating 
telogen (resting) hair follicles. When tile m ice entered anagen, ha.ir 
regrowth b egan just as described previously [8], as detected by 
increasin g skin pigmentation, i.e., gray to black. After the mice 
were treated topically with 1 {.Lmol FK506 o n days 0 and 3, 50% of 
the tested animals entered anagcn b y day 9 and 100% by day 16 
(Fig 1). With 0.1 {.Lmol of FK506, 50% of the tested mice entered 
anagen b y day 13 and 80% by day 19 (Fig 1), indicating that the 
effect of FK506 was dose dependent. In the control animals, a 
spontaneous sluft fi·om telogen to anagen sta.rted on day 14 . a.l1d 
30'!!o were in anagen phase at day 19 (Fig 1). These results indicate 
t h e induction of anagen by FK506. 
Figure 2 and Table I show the histology and the quantitative 
morphometric data, respectively, for the control and FK506-treated 
mouse skin. As is clearly shown, FK506 treatment markedly 
stimulated the skin and t1uckened it, witllout inducing an inRanunatory 
reaction . The deptll and size of hair follicles were also markedly 
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Figurc 1. Induction of anagcn in tclogcn micc by topical applica-
tion of FK506. FK506, 0.1 fLmol (open 'circles) or 1 fLmol (closed circles), or 
vehjcle (acetone; triflllgles) was applied topically to the dorsa l skin of tclogen 
C57BL/6] mice (7 weeks of age) once each on days 0 and 3. The number 
of animals in te logen or anagen, as judged by their skin color, i.e., brigh t 
pink in telogen and gray to black in anagen , was counted and expressed as 
percentage of anjmals in anagen . Each group consisted of lO animals. All the 
experiments were repeated twice, and the results were reproducible. 
increased in FK506-treated skin compared to control skin (Fig 2; 
Table 1). It has been reported that skin thickness increases from a thin 
telogen skin to a thickened anagen skin [8,9] and that the size and 
depth of follicles are markedly increased in anagen phase 19,10]. 
Changes in the hair length after FK506 treatment were also seen (Fig 
3). FKS06 markedly stimulated hair growth, consistent with our 
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F igurc 2. Histology of FK506-trcatcd mousc skin. Vehjcle (acetone) 
(A) or FK506 (1 fLmol) (B) was app li ed topica lly to tclogen C57BLi6J mice 
(7 weeks of age) once each on days 0 and 3. At day 15 , skin was taken for 
histo logic cxam i.nation. Each section was stained with hematoxylin and 
eosin. Magntlication X 25 . 
T H E JO UI1.NAL OF INVESTIGATIVE DER.MATOLOGY 
Table I. Comparison of Total Dermal Thickness and 
Hair Follicle Depth Between Control (Acetone-Treated) 
and FK506-Treated Mouse Skin" 
Total Dermal Hair Follicle 
T hickness" Depth/' 
Day Treatment (fLlII) (fL/II) 
0 None 388 :!: 9 172 :!: 8 
8 Acetone 382 :!: 4' 164 :!: 7' 
8 FK506,0.1 fLmol 490 :!: 16" 311 :!: 20'/ 
15 Acetone 398 :!: 15' 167 :!: 8' 
15 FK506, 0.1 fLmol 719 :!: 22" 548 :!: 22'/ 
15 FK506, 1 fLmol 662 :!: 19" 535 :!: 17'/ 
"FK50G was applied topically to the dorsaJ skin 0 [ C57BLl6] mice (7 weeks of age) 
o n days 0 and 3 . 
b Valu es ;Irc expressed as mean :!: SEM (11 = 15- 22) from three mice . 
, Not significantly different versus none (day 0). 
d P < 0.0 I versus corresponding control (acetone). 
previous obselvations [3]. T he hair produced looked nomlal, and the 
hairs were of nonna! length (Fig 3). Moreover, the hair growth was 
restt;cted to the site of application (Fig 4). All of these resuJts clearly 
demonstrate that topical application of FKS06 induces anagen hair 
growth in teiogen mouse skin . 
As reported previously, topical application of FK506 markedly 
stimulates hair growth in mice, rats, and hamsters [3]. III lJitro 
studies have revealed that FKS06 stimulates eH]thymidine and 
eH]glycine uptake in the hair follicles [3]. Qur present results 
indicate that the hair-growth-stim ulating effect of FK506 is due at 
least in part to its promoting effect on the hair cycle. 
Another T - celJ-specifi c immunosuppressant, cyclosporin A 
(CsA), also stimulates hair growth both in l aborat~ry animals 
[8,11- 13] and in humans [14-18]. Hypertrichosis is a welJ-known 
side efl:cct of CsA [14-18]. Moreover, CsA also iJlduces anagen in 
te logen mouse skin [8] . Beca use of these findings, one can speculate 
that the immunosuppressive effect of FK506 is re lated to its 
stimula tion of hair growth . However, the hair- growth-stimulating 
e fl:e ct of FKS06 does not occur after ora l administration of an 
immunosuppressive dose of tlus drug [3] . Furthermore, FK506 
stimulates hair growth even in SCID mice, wluch lack both B- and 
T-celJ immunity [3]. Therefore, it seem s unljke ly that the hair 
growth-stimulating e ffect of FKS06 is related to its immunosup-
pressive effect [3]. 
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Figurc 3. Changes in hair length after topical application ofFK506 
in tclogcn micc. The dorsa l hair of C57BL/6] mice (7 weeks of age) was 
shaved w ith clippers 2 d before day O. FK506 (1 fLmol ; opell circles) o r vehicle 
(acetone; closed circles) was app lied topically on days 0 and 3. T";(/lIgles 
indicate non-shaved control mice (without treatment). Values arc expressed 
as mean :!: SEM of 35 hairs from four mice. 
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-Acetone FKS06 (0.1 Ilmol) 
Figure 4. Hair growth is restricted to the site of topical application 
in FK506-treated C57BL/6] mice. FK506 (0.1 !Llllo l) or vehicle (ace-
tone) was applied topically only to the longitudinal cen ter of the shaved area 
on days 0 and 3 . T he Illacrophotograph was taken 3 weeks after the 
application. 
Both FK506 and CsA exert their immunosuppressive effects 
through inhibition of T-cell activation, interfering with the pro-
duction of inte rleukin-2 by inhibi tin g interleukin-2 gen e expression 
[1 ,2,19,20]. FK506 and CsA initially bind to intracellular binding 
proteins , i. e., FK506-bindjng protein and cyclophilin, respectively 
[21-24]. Both FK506-binding protein and cyclophilin, al so called 
immunophilins, are identical to peptidyl-prolyl isom erase 
[21,22,25,26], i.e., rotamase, an enzyme that catalyzes the inter-
conversion of the cis- and Imlls- rotamers of the peptidyl am ide bond 
of peptides . Rotamase activity is inhibited by these immunosup-
pressants [21,25,26]; howeve~, this .in.l:ibition is essentially unre-
lated to the immunosuppressive actlvloes of these drugs [27,28]. 
Both FK506/FK506-binding prote in and CsA/ cyclophilin com-
plexes bind to Ca + + - and calmodulin-dependent serine/threonine 
phosphatase calcineurin , resulting in inhibition of the phosphatase 
activity [29]. Inhibitio n of calcin eurin by FK506 and CsA sup-
presses the assembly of the T -cell-specifi c tran scription factor of 
the interleukin-2 gene, i.e., N F-AT, leading to the inhibition of 
interleukin-2 gene expression [3 0]. 
At present, the precise mechanism of the hair-growth-stil11ulat-
ing effect of FK506 is unknown. Moreover, it is also unclear 
whether FK506 and CsA stimulate hair growth through a common 
mechanis111. Because cyclophilin , FK506-binding protein , and C<11-
cin eurin m'e abundant and ubiquitous proteins, it sho uld be con-
sidered that im111unoph.i.lin-related o r il11l11unophilin/ calcineurin-
related mechanisms are involved in the hair-growth-sti l11ulating 
effects ofFK506 and CsA. Further studies are now under way in our 
laboratory to elucidate the precise mechanism . 
Tltis sl,lIdy IIIas SlIppo,ted ill pari by a grnlll jimll lite Millislly (if Edllcal;'JII, Scicllee, 
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